Coronavirus vaccine update: Pfizer-BioNTech looking at COVID vaccine candidate with ‘fewest side effects’

By: |
New Delhi | August 21, 2020 9:48 AM

Coronavirus vaccine update: Pfizer and BioNTech have plans to supply up to 100 million doses of vaccine worldwide by the end of 2020

coronavirus vaccine, coronavirus vaccine in India, coronavirus vaccine update, coronavirus vaccine tracker, coronavirus vaccine news, coronavirus vaccine trials, coronavirus vaccine name, coronavirus vaccine who, covid19 vaccine, covid19 vaccine India, covid19 vaccine news, covid19 vaccine update, covid19 vaccine oxford, covid19 vaccine tracker, covid19 vaccine status in India, covid19 vaccine progressCoronavirus vaccine update: Pfizer-BioNTech has begun the final stages of Human Trials on around 30,000 people in the US and other countries. (Reuters image)

Coronavirus vaccine update: In a ray of hope, US-based Pfizer and German’s BioNTech are looking at an experimental coronavirus vaccine that will have “fewest side effects”. Pfizer-BioNTech’s potential vaccine against COVID19 has already entered phase 3 human clinical trials stage. Explaining the data obtained during the early stage of the clinical trials, Pfizer researchers have said that immune systems were revived and there were no side effects, according to a report by Associated Press. Along with Oxford-AstraZeneca and Moderna, Pfizer-BioNTech is considered to have made significant grounds in developing the elusive vaccine against the highly contagious vaccine.

During the phase 1 study, Pfizer-BioNTech’s COVID vaccine candidate BNT162b2 managed to elicit SARS-CoV-2–neutralising geometric mean titers (GMTs) in younger adults (18-55 years of age) that were 3.8 times the GMT of a panel of 38 sera of SARS-CoV-2 convalescent patients. In older adults (65-85 years of age) the vaccine candidate elicited a neutralizing GMT 1.6 times the GMT of the same panel, demonstrating strong immunogenicity in younger and older adults, the data published by Pfizer-BioNTech on its website says.

Across all volunteers on whom the vaccine candidate was administered, Pfizer-BioNTech’s BNT162b2 administration was found to be well tolerated with “mild to moderate fever in fewer than 20 per cent of the participants”. Pfizer and BioNTech claimed that they have initiated a process to seek regulatory review of its potential coronavirus candidate ‘BNT162b2’ as early as October 2020. If regulatory authorization or approval is obtained, Pfizer and BioNTech have plans to supply up to 100 million doses worldwide by the end of 2020 and approximately 1.3 billion doses by the end of 2021, Pfizer-BioNTech says in its report.

Pfizer-BioNTech has begun the final stages of Human Trials on around 30,000 people in the US and other countries. Till date, the fastest vaccine has been developed in four years. Health officials in the US are expecting to begin the vaccination programme in 2021.

Around the world, more than 165 experimental coronavirus vaccines are mat different stages of development. So far, 32 vaccines have managed to enter the human trials phase.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Bharat Biotech says current price of Covaxin not sustainable
2Delta Plus variant of virus identified, to be tracked
3Those in 1-20 age group accounted for less than 12 per cent of Covid cases during both waves: Govt